-
E649974-10mgElubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation ( IC 50 of 260.7 nM) and shape
-
E649974-25mgElubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation ( IC 50 of 260.7 nM) and shape
-
E649974-50mgElubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation ( IC 50 of 260.7 nM) and shape
-
E649974-5mgElubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation ( IC 50 of 260.7 nM) and shape
-
L647680-10mgLadarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma.In VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)
-
L647680-25mgLadarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma.In VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)
-
L647680-5mgLadarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma.In VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)
-
L655130-1mlLadarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma.In VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)
-
L651287-100mgLadarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthmaIn VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)
-
L651287-10mgLadarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthmaIn VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)
-
L651287-25mgLadarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthmaIn VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)
-
L651287-50mgLadarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthmaIn VitroLadarixin inhibits human polymorphonuclear leukocyte (PMN)